ABSTRACT In a randomised, controlled study alternate day prednisolone with an initial high dose phase ("prednisolone only series") has been compared with cyclophosphamide plus alternate day low dose prednisolone ("cyclophosphamide-prednisolone series") in 43 patients with previously untreated fibrosing alveolitis (five patients had received prednisolone in minimal dosage). In the prednisolone only series prednisolone 60 mg daily was given for one month and then reduced by 5 mg a week to 20 mg on alternate days or the minimum dose to maintain early improvement. Patients in the cyclophosphamide-prednisolone series received 100, 110, or 120 mg cyclophosphamide daily (depending on body weight) plus 20 mg prednisolone on alternate days. Treatment was continued indefinitely, or changed to the alternative regimen if the patient deteriorated, failed to improve, or developed drug toxicity. For response to treatment (as judged by change in breathlessness score, radiographic appearance, and lung function) patients were classified as improved, stable, or deteriorating. Deaths from cryptogenic fibrosing alveolitis were also analysed.
Prednisolone compared with cyclophosphamide and low dose prednisolone in cryptogenicfibrosing alveolitis 281 Introduction Cryptogenic fibrosing alveolitis (idiopathic pulmonary fibrosis) is a disorder with an almost invariably poor prognosis.' Untreated patients in a previous retrospective study had a median survival of only 54 months.2 In uncontrolled studies a small proportion of patients have been found to respond to treatment with corticosteroids, and this response was also related to improved survival time."7The features associated with steroid responsiveness in the retrospective study were younger age, female sex, and a more cellular histological appearance (though not necessarily characteristic of desquamative interstitial pneumonia).2 Improvement has been reported to be associated with a greater number of intra-alveolar large mononuclear cells and less fibrosis in biopsy specimens.7 Some patients respond only transiently to treatment with high dose corticosteroids and most show no response. Long term treatment with high dose corticosteroids is complicated by side effects, some of them serious and causing permanent sequelae. Alternative forms of treatment for this disorder are therefore desirable.
Some reports ofuncontrolled studies have indicated that cyclophosphamide and other immunosuppressant drugs may be as effective as corticosteroids and may have less serious side effects. Cyclophosphamide, azathioprine, and chlorambucil have all been reported to produce objective evidence of improvement." '3 Patients have also been reported to respond to immunosuppressant agents after having failed to respond to steroids.9 [11] [12] [13] The addition of an immunosuppressant agent has led to further improvement in corticosteroid responsive patients. 9 The aim of this randomised controlled study was to compare the efficacy and side effects of cyclophosphamide in combination with low dose alternate day prednisolone with those of alternate day prednisolone alone (including an initial high dose phase) in patients with previously untreated fibrosing alveolitis ( < 30 mg prednisolone for one month).
Methods

PATIENTS
All patients with cryptogenic fibrosing alveolitis who were referred to the department of medicine at the Brompton Hospital during 1980-4 were admitted to hospital and assessed for entry into the study. Patients who had ever previously received prednisolone in a dose of 30 mg daily for more than one month were not eligible, nor were patients who had received an immunosuppressant drug. The diagnostic criteria for cryptogenic fibrosing alveolitis were those of TurnerWarwick and Haslam14 and the diagnosis was confirmed whenever feasible by open lung biopsy. Patients were excluded if they were positive in the avian precipitin test or had a relevant occupational exposure. Patients were not eligible if they were pregnant or wished to have children in the near future, or if they had coincidental malignant disease, diabetes mellitus, or active tuberculosis. In addition, patients were not eligible if either regimen was contraindicated on clinical grounds.
Of the 78 patients referred, 45 were eligible for admission to the trial, of whom 43 were enrolled. Of those excluded, 19 had previously received treatment, seven were not suitable for one or other regimen, and seven had other final diagnoses. Of the 43 patients enrolled, 38 had never been treated, three had received 30 mg prednisolone or less daily for one month or less in the past but were no longer having any treatment, and two patients (one in the high dose prednisolone and the other in the cyclophosphamide plus prednisolone series) were receiving prednisolone 5 mg daily and 10 mg daily respectively at the time of enrolment. Thirty three patients had had an open lung biopsy, two a drill biopsy, and one a transbronchial biopsy. On entry to the study patients gave their informed consent and the approval of the ethical committee was obtained. Patients were allocated at random to treatment with one of the two following regimens ( 18 point scale overall. The UC-ILO system has been used in other non-occupational lung diseases, with radiographic features similar to those of cryptogenic fibrosing alveolitis. '8 In addition, the chest radiographs were reviewed in known order, but without knowledge of other clinical details, to assess the amount of change from the pretreatment film on a scale of -3 (substantial deterioration) to + 3 (substantial improvement), 0 being "no change."
Open lung biopsy specimens when available were graded by an independent assessor (BEH) without knowledge of treatment, as described by Wright et al.7 When bronchoalveolar lavage was carried out, the lavage procedure, preparation of samples, and the cell count method were those described previously. '9 Patients were reviewed one month after starting treatment, at three months and subsequently at three monthly intervals for two years and six monthly thereafter (or more often if clinically indicated). Patients completed self assessment forms at weekly intervals for the first three months and monthly thereafter, recording cough, sputum, and breathlessness (on the same scale). Clinical response was assessed at each attendance by the chief investigator (MT-W) or deputy and was based on clinical findings, chest radiographs, and pulmonary function measurements, including progressive exercise tests with blood gas tension measurements and walking tests whenever possible. Bronchoalveolar lavage specimens were obtained at the three and 12 month assessment if the regimen had not been changed. Patients Total patients 22 21 P-prednisolone; C-cyclophosphamide; FVC-forced vital capacity; TLC-total lung capacity; TLcO-transfer factor for carbon monoxide; Kco-transfer coefficient.
Of the 21 patients allocated to the cyclophosphamideprednisolone regimen, five improved. One patient was first classified as having improved at three months and four patients at the 12 month assessment. Two of the patients subsequently deteriorated between 12 and 24 months and one remained stable at five years. The remaining two patients developed toxicity after two solone series (one patient in this series was still on the allocated regimen despite having deteriorated) (fig 1) . Three further patients from the cyclophosphamideprednisolone series had stopped their cyclophosphamide because of toxicity but remained stable.
SURVIVAL ANALYSIS
There was a suggestion of improved survival in patients allocated to the cyclophosphamide-prednisolone regimen (fig 2) but this was not significant (p > 0-1).
Analysis ofthe data with respect to time until failure ofthe first treatment regimen or death showed that this was significantly longer for the patients allocated to the cyclophosphamide-prednisolone series (p < 0 05); at three years, for example, 53% of the patients initially allocated to cyclophosphamide-prednisolone were still having their allocated treatment or receiving no treatment, compared with 24% of the patients in the prednisolone only series (fig 3) .
The only factors significantly associated with time to "failure" in the Cox regression analyses were initial FVC and TLC (p < 0 05 for both). Patients with a TLC of 80% or more of the predicted value did well, with no suggestion of difference between the two regimens ( fig 3) . Patients with an initial TLC below 60% predicted did badly in terms of time to "failure" regardless of the initial regimen, all patients having died or changed regimen by two years. Patients with a TLC of 60-79% predicted did significantly better in the cyclophosphamide-prednisolone series than in the prednisolone only series (p < 0-05).
Survival was also compared for patients initially allocated to the cyclophosphamide-prednisolone regimen and those who were initially allocated to prednisolone only but who were subsequently changed to the cyclophosphamide-prednisolone regimen because of treatment failure. Patients who received cyclophosphamide as part of their first treatment . .---.
---. . 21 receiving cyclophosphamide plus prednisolone (C + P); (b) 9 P, 3 C + P; (c) 7 P, 8 C + P; (d) 6 P, 10 C + P.
regimen survived longer than patients who received it after failure of the prednisolone only regimen (the difference appears to be entirely accounted for by TLC % predicted and breathlessness grade at the time of starting cyclophosphamide).
DEATHS
Of the 22 patients in the prednisolone only series, 15 have died so far (table 4). Eleven died from fibrosing alveolitis, one from carcinoma of the bronchus, one from cerebral metastases from an unknown primary tumour, and the remaining two patients from other causes unrelated to treatment. In the cyclophosphamide-prednisolone series there have also been 15 deaths; eight patients have died from fibrosing alveolitis, two from bronchial carcinoma, and five from other causes unrelated to treatment. At three years 10 of 22 patients in the prednisolone only series compared with three of 21 in the cyclophosphamideprednisolone series had died from fibrosing alveolitis. prednisolone only regimen could be criticised on the basis that the maintenance dose (20 mg on alternate days) was too low. This level, however, was reached only after much larger doses had been given on a daily basis for at least three months, during which time the patients had been assessed for improvement on at least two occasions.
The population referred to this tertiary referral hospital for assessment may be biased towards those with more severe disease. There was almost invariably a delay before patients were referred for initial evaluation. In addition, some physicians had treated patients with low doses of prednisolone before referral and they may not have sent patients who responded to similar doses of prednisolone for evaluation. Indirect evidence that some of the potentially most steroid responsive patients may not have been referred to us is suggested by the fact that only four of the 40 patients who underwent bronchoalveolar lavage had an increased lymphocyte count in pretreatment lavage specimens. Recent evidence suggests that this group is the most responsive to corticosteroid treatment.2223 An additional indication of this bias is the predominance of men, as they have been shown to respond less well.2 For ethical reasons we excluded younger patients who intended having children in the near future from the random allocation. This prevented us from observing the value of cyclophosphamide in such patients.
We could not use a fully double blind design because it was judged unethical to require patients taking high dose prednisolone to have fortnightly blood tests. The obvious facial mooning caused by prednisolone treatment and the macrocytosis of those having cyclophosphamide would in any case have made the treatment regimens obvious. In a trial which is not double blind it is crucial that those responsible for management do not introduce a bias towards one or other regimen by using different criteria when making the decision to change a patient to the alternative limb ofthe trial. The possibility of such bias was examined during the course of the trial. Unnamed charts were constructed from the collected data, including results of radiographic change (assessed independently), pulmonary function measurements, and patients' serial selfassessments. The clinical supervisor was then asked to decide on the basis of these data, and without knowledge of which drug was being used at the time, whether a change in the drug regimen should have been made at various time points. In this analysis there was no suggestion that the decisions on whether to change regimen that were made on the basis of the reconstructed clinical information were different from those taken by the same clinical supervisor during the course of the trial.
The problems of maintaining any trial over many years are formidable, particularly when the number of
